title: Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines.
abstract: OBJECTIVE
  To provide recommendations on prevention, screening, genetics, treatment, and management for people at risk for hereditary colorectal cancer (CRC) syndromes. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.
  
  
  METHODS
  The Familial Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published in 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Annals of Oncology was reviewed for developmental rigor by methodologists, with content and recommendations reviewed by an ASCO endorsement panel.
  
  
  RESULTS
  The ASCO endorsement panel determined that the recommendations of the ESMO guidelines are clear, thorough, and based on the most relevant scientific evidence. The ASCO panel endorsed the ESMO guidelines and added a few qualifying statements.
  
  
  CONCLUSIONS
  Approximately 5% to 6% of patient cases of CRC are associated with germline mutations that confer an inherited predisposition for cancer. The possibility of a hereditary cancer syndrome should be assessed for every patient at the time of CRC diagnosis. A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can influence clinical management for patients with CRC and their family members. Screening for hereditary cancer syndromes in patients with CRC should include review of personal and family histories and testing of tumors for DNA mismatch repair deficiency and/or microsatellite instability. Formal genetic evaluation is recommended for individuals who meet defined criteria.
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Elena M
authors.initials: EM
authors.lastname: Stoffel
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Pamela B
authors.initials: PB
authors.lastname: Mangu
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Gruber
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Stanley R
authors.initials: SR
authors.lastname: Hamilton
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Matthew F
authors.initials: MF
authors.lastname: Kalady
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Michelle Wan Yee
authors.initials: MW
authors.lastname: Lau
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Karen H
authors.initials: KH
authors.lastname: Lu
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Nancy
authors.initials: N
authors.lastname: Roach
authors.affiliation: Elena M. Stoffel, University of Michigan, Ann Arbor, MI; Pamela B. Mangu, American Society of Clinical Oncology; Nancy Roach, Fight Colorectal Cancer, Alexandria, VA; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Stanley R. Hamilton and Karen H. Lu, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew F. Kalady, Cleveland Clinic, Cleveland, OH; Michelle Wan Yee Lau, Integrated Medical Services Four Winds Hematology and Oncology, Tempe, AZ; and Paul J. Limburg, Mayo Clinic, Rochester, MN.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Limburg
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000175:diagnosis* / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*; D025601:Adenomatous Polyposis Coli Protein / Q000235:genetics; D016588:Anticarcinogenic Agents / Q000008:administration & dosage; D018890:Chemoprevention / Q000379:methods; D003113:Colonoscopy; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000175:diagnosis* / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*; D045647:DNA Glycosylases / Q000235:genetics; D053843:DNA Mismatch Repair; D055088:Early Detection of Cancer / Q000379:methods; D005817:Genetic Counseling; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D018095:Germ-Line Mutation; D006579:Heterozygote; D006801:Humans; D008487:Medical History Taking; D053842:Microsatellite Instability; D011159:Population Surveillance / Q000379:methods; D012812:Sigmoidoscopy
chemical_list: C555337:APC protein, human; D025601:Adenomatous Polyposis Coli Protein; D016588:Anticarcinogenic Agents; D045647:DNA Glycosylases; C061738:mutY adenine glycosylase